Patents by Inventor Cornelis Johannes Leenhouts
Cornelis Johannes Leenhouts has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11918683Abstract: The present invention relates to the treatment of autoimmune and allergic diseases by oromucosal administration of a formulation consisting of an optimized combination of antigen, tolerizing agent and mucoadhesive carrier for each immune disease indication.Type: GrantFiled: December 1, 2022Date of Patent: March 5, 2024Assignee: Allero Therapeutics B.V.Inventors: Emil Richard George Pot, Cornelis Johannes Leenhouts, Poul Sörensen
-
Publication number: 20230149305Abstract: The present invention relates to the treatment of autoimmune and allergic diseases by oromucosal administration of a formulation consisting of an optimized combination of antigen, tolerizing agent and mucoadhesive carrier for each immune disease indication.Type: ApplicationFiled: December 1, 2022Publication date: May 18, 2023Inventors: Emil Richard George Pot, Cornelis Johannes Leenhouts, Poul Sörensen
-
Patent number: 11547662Abstract: The present invention relates to the treatment of autoimmune and allergic diseases by oromucosal administration of a formulation consisting of an optimized combination of antigen, tolerizing agent and mucoadhesive carrier for each immune disease indication.Type: GrantFiled: October 25, 2018Date of Patent: January 10, 2023Assignee: Allero Therapeutics B.V.Inventors: Emil Richard George Pot, Cornelis Johannes Leenhouts, Poul Sörensen
-
Publication number: 20210030664Abstract: The present invention relates to the treatment of autoimmune and allergic diseases by oromucosal administration of a formulation consisting of an optimized combination of antigen, tolerizing agent and mucoadhesive carrier for each immune disease indication.Type: ApplicationFiled: October 25, 2018Publication date: February 4, 2021Applicant: Allero Therapeutics B.V.Inventors: Emil Richard George Pot, Cornelis Johannes Leenhouts, Poul Sörensen
-
Patent number: 9878034Abstract: The invention relates to adjuvanted vaccine formulations, in particular influenza vaccines for intranasal delivery. Provided is an adjuvanted influenza vaccine formulation, comprising (i) peptidoglycan microparticles obtained from a Gram-positive bacterium and (ii) at least one influenza virus antigen or antigenic preparation thereof, which antigen or antigenic preparation is not fused or otherwise covalently attached to a proteinaceous peptidoglycan binding moiety.Type: GrantFiled: October 1, 2010Date of Patent: January 30, 2018Assignee: MUCOSIS B.V.Inventors: Govert Johan Schouten, Cornelis Johannes Leenhouts
-
Patent number: 9585953Abstract: The invention relates to the field of immunology and vaccine development, in particular to the development of vaccines based on native antigen oligomers. Provided is an immunogenic composition in particulate form, comprising oligomers of a surface exposed polypeptide of pathogenic origin or tumor origin, or antigenic part thereof, said oligomers being bound non-covalently to a particulate carrier, and a pharmaceutically acceptable diluent or excipient.Type: GrantFiled: March 22, 2012Date of Patent: March 7, 2017Assignee: MUCOSIS B.V.Inventors: Cornelis Johannes Leenhouts, Bert Jan Haijema, Maarten Leonardus van Roosmalen, Petrus Josephus Marie Rottier, Cornelis Alexander Maria de Haan, Berend Jan Bosch
-
Patent number: 9549974Abstract: The invention relates to the field of vaccines against microbial infections and especially bacterial vaccines, in particular to pneumococcal vaccines. More in particular, the invention relates to means and methods to identify, select and isolate a vaccine component for passive and/or active immunization against a microorganism that can be killed by opsonophagocytic cells. The invention relates to a method to identify an opsonophagocytosis inducing antigen as a vaccine component for immunization against a microorganism. The invention describes three pneumococcal proteins SlrA, IgA1 proteinase, and PsaA, and their use as a vaccine component with or without PpmA. The invention also discloses the use of antibodies against said proteins for passive immunization and diagnosis.Type: GrantFiled: February 15, 2012Date of Patent: January 24, 2017Assignee: MUCOSIS B.V.Inventors: Cornelis Johannes Leenhouts, Ronald de Groot, Peter Wilhelmus Maria Hermans
-
Publication number: 20160136294Abstract: The disclosure relates to the areas of immunology and vaccine delivery. More specifically, it relates to a bacterial vaccine delivery technology with built-in immunostimulatory properties which allow the immobilization of any antigen of interest, without prior antigen modification. Provided is an antigen-loaded immunogenic carrier complex comprising at least one bifunctional polypeptide attached to an immunogenic carrier, the bifunctional polypeptide comprising a peptidoglycan binding domain (PBD) through which the polypeptide is attached to the carrier, fused to an antigen binding domain (ABD) to which at least one antigen of interest is bound. Also described is a pharmaceutical (e.g., vaccine) composition comprising an antigen-loaded immunogenic carrier complex.Type: ApplicationFiled: January 19, 2016Publication date: May 19, 2016Inventors: Cornelis Johannes Leenhouts, Maarten Leonardus Van Roosmalen, Tjibbe Bosma
-
Publication number: 20150196659Abstract: The disclosure relates to the areas of immunology and vaccine delivery. More specifically, it relates to a bacterial vaccine delivery technology with built-in immunostimulatory properties which allow the immobilization of any antigen of interest, without prior antigen modification. Provided is an antigen-loaded immunogenic carrier complex comprising at least one bifunctional polypeptide attached to an immunogenic carrier, the bifunctional polypeptide comprising a peptidoglycan binding domain (PBD) through which the polypeptide is attached to the carrier, fused to an antigen binding domain (ABD) to which at least one antigen of interest is bound. Also described is a pharmaceutical (e.g., vaccine) composition comprising an antigen-loaded immunogenic carrier complex.Type: ApplicationFiled: March 24, 2015Publication date: July 16, 2015Inventors: Cornelis Johannes LEENHOUTS, Maarten Leonardus VAN ROOSMALEN, Tjibbe BOSMA
-
Patent number: 9011870Abstract: The invention relates to the areas of immunology and vaccine delivery. More specifically, it relates to a bacterial vaccine delivery technology with built-in immunostimulatory properties which allows the immobilization of any antigen of interest, without prior antigen modification. Provided is an antigen-loaded immunogenic carrier complex comprising at least one bifunctional polypeptide attached to an immunogenic carrier, said bifunctional polypeptide comprising a peptidoglycan binding domain (PBD) through which the polypeptide is attached to said carrier, fused to an antigen binding domain (ABD) to which at least one antigen of interest is bound. Also provided is a pharmaceutical (e.g. vaccine) composition comprising an antigen-loaded immunogenic carrier complex of the invention.Type: GrantFiled: July 20, 2006Date of Patent: April 21, 2015Assignee: Applied Nanosystems B.V.Inventors: Cornelis Johannes Leenhouts, Maarten Leonardus Van Roosmalen, Tjibbe Bosma
-
Publication number: 20140093532Abstract: The invention relates to the field of immunology and vaccine development, in particular to the development of vaccines based on native antigen oligomers. Provided is an immunogenic composition in particulate form, comprising oligomers of a surface exposed polypeptide of pathogenic origin or tumour origin, or antigenic part thereof, said oligomers being bound non-covalently to a particulate carrier, and a pharmaceutically acceptable diluent or excipient.Type: ApplicationFiled: March 22, 2012Publication date: April 3, 2014Applicant: MUCOSIS B.V.Inventors: Cornelis Johannes Leenhouts, Bert Jan Haijema, Maarten Leonardus Van Roosmalen, Petrus Josephus Marie Rottier, Cornelis Alexander Maria De Haan, Berend Jan Bosch
-
Publication number: 20120301501Abstract: The invention relates to the field of biology, more specifically to the field of immunology and microbiology. The invention further relates to the field of vaccines against microbial infections and especially bacterial vaccines, in particular to pneumococcal vaccines. More in particular, the invention relates to means and methods to identify, select and isolate a vaccine component for passive and/or active immunisation against a microorganism that can be killed by opsonophagocytic cells. The invention relates to a method to identify an opsonophagocytosis inducing antigen as a vaccine component for immunisation against a microorganism. The invention describes three pneumococcal proteins SlrA, IgA1 proteinase, and PsaA, and their use as a vaccine component with or without PpmA. The invention also discloses the use of antibodies against said proteins for passive immunization and diagnosis.Type: ApplicationFiled: February 15, 2012Publication date: November 29, 2012Applicant: MUCOSIS B.V.Inventors: Cornelis Johannes Leenhouts, Ronald de Groot, Peter Wilhelmus Maria Hermans
-
Publication number: 20120219586Abstract: The invention relates to adjuvanted vaccine formulations, in particular influenza vaccines for intranasal delivery. Provided is an adjuvanted influenza vaccine formulation, comprising (i) peptidoglycan microparticles obtained from a Gram-positive bacterium and (ii) at least one influenza virus antigen or antigenic preparation thereof, which antigen or antigenic preparation is not fused or otherwise covalently attached to a proteinaceous peptidoglycan binding moiety.Type: ApplicationFiled: October 1, 2010Publication date: August 30, 2012Inventors: Govert Johan Schouten, Cornelis Johannes Leenhouts
-
Patent number: 8142789Abstract: The invention relates to the field of biology, more specifically to the field of immunology and microbiology. The invention further relates to the field of vaccines against microbial infections and especially bacterial vaccines, in particular to pneumococcal vaccines. More in particular, the invention relates to means and methods to identify, select and isolate a vaccine component for passive and/or active immunisation against a microorganism that can be killed by opsonophagocytic cells. The invention relates to a method to identify an opsonophagocytosis inducing antigen as a vaccine component for immunisation against a microorganism. The invention describes three pneumococcal proteins SlrA, IgAl proteinase, and PsaA, and their use as a vaccine component with or without PpmA. The invention also discloses the use of antibodies against said proteins for passive immunization and diagnosis.Type: GrantFiled: May 17, 2004Date of Patent: March 27, 2012Assignee: Mucosis B.V.Inventors: Cornelis Johannes Leenhouts, Ronald de Groot, Peter Wilhelmus Maria Hermans
-
Publication number: 20110044982Abstract: The invention relates to the field of immunology and vaccines. In particular, it relates to proteinaceous substances and the uses thereof in vaccines against infections caused by respiratory pathogens.Type: ApplicationFiled: September 22, 2009Publication date: February 24, 2011Inventors: Cornelis Johannes Leenhouts, Maarten Leonardus van Roosmalen, Govert Johan Schouten
-
Patent number: 7858357Abstract: Methods for improving binding of a proteinaceous substance to cell-wall material of a Gram-positive bacterium are disclosed. The proteinaceous substance includes an AcmA cell-wall binding domain, homolog or functional derivative thereof. The method includes treating the cell-wall material with a solution capable of removing a cell-wall component such as a protein, lipoteichoic acid or carbohydrate from the cell-wall material and contacting the proteinaceous substance with the cell-wall material.Type: GrantFiled: May 1, 2009Date of Patent: December 28, 2010Assignee: Applied NanoSystems B.V.Inventors: Cornelis Johannes Leenhouts, Ranjan Ramasamy, Anton Steen, Jan Kok, Girbe Buist, Oscar Paul Kuipers
-
Publication number: 20090263414Abstract: The invention relates to the areas of immunology and vaccine delivery. More specifically, it relates to a bacterial vaccine delivery technology with built-in immunostimulatory properties which allows the immobilization of any antigen of interest, without prior antigen modification. Provided is an antigen-loaded immunogenic carrier complex comprising at least one bifunctional polypeptide attached to an immunogenic carrier, said bifunctional polypeptide comprising a peptidoglycan binding domain (PBD) through which the polypeptide is attached to said carrier, fused to an antigen binding domain (ABD) to which at least one antigen of interest is bound. Also provided is a pharmaceutical (e.g. vaccine) composition comprising an antigen-loaded immunogenic carrier complex of the invention.Type: ApplicationFiled: July 20, 2006Publication date: October 22, 2009Inventors: Cornelis Johannes Leenhouts, Maarten Leonardus Van Roosmalen, Tjibbe Bosma
-
Publication number: 20090239264Abstract: Methods for improving binding of a proteinaceous substance to cell-wall material of a Gram-positive bacterium are disclosed. The proteinaceous substance includes an AcmA cell-wall binding domain, homolog or functional derivative thereof. The method includes treating the cell-wall material with a solution capable of removing a cell-wall component such as a protein, lipoteichoic acid or carbohydrate from the cell-wall material and contacting the proteinaceous substance with the cell-wall material.Type: ApplicationFiled: May 1, 2009Publication date: September 24, 2009Applicant: Applied NanoSystems B.V.Inventors: Cornelis Johannes Leenhouts, Ranjan Ramasamy, Anton Steen, Jaa Kok, Girbe Buist, Oscar Paul Kuipers
-
Patent number: 7541039Abstract: Methods for improving binding of a proteinaceous substance to cell-wall material of a Gram-positive bacterium are disclosed. The proteinaceous substance includes an AcmA cell-wall binding domain, homolog or functional derivative thereof. The method includes treating the cell-wall material with a solution capable of removing a cell-wall component such as a protein, lipoteichoic acid or carbohydrate from the cell-wall material and contacting the proteinaceous substance with the cell-wall material.Type: GrantFiled: December 9, 2005Date of Patent: June 2, 2009Assignee: Applied NanoSystems, B.V.Inventors: Cornelis Johannes Leenhouts, Ranjan Ramasamy, Anton Steen, Jan Kok, Girbe Buist, Oscar Paul Kuipers
-
Patent number: 7169383Abstract: The invention relates to surface display of proteins on micro-organisms via the targeting and anchoring of heterologous proteins to the outer surface of cells such as yeast, fungi, mammalian and plant cells, and bacteria. The invention provides a proteinaceous substance comprising a reactive group and at least one attaching peptide which comprises a stretch of amino acids having a sequence corresponding to at least a part of the consensus amino acid sequence listed in FIG. 10 and comprises a method for attaching a proteinaceous substance to the cell wall of a micro-organism comprising the use of said attaching peptide.Type: GrantFiled: November 12, 1998Date of Patent: January 30, 2007Assignee: Applied Nanosystems B.V.Inventors: Girbe Buist, Cornelis Johannes Leenhouts, Gerard Venema, Jan Kok